We were privileged to welcome Professor Christoph Zielinski as our latest speaker in the invIOs Innovation Lectures. One of Europe's most distinguished medical oncologists, Professor Zielinski shared with us insights...

APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver treatment in under 24 hours Data...

Today we're unveiling our new Scientific Advisory Board (SAB), which brings together five leading European cancer experts to help fast-forward our growth. The SAB is a multi-disciplinary formation with cross-cutting knowledge...

Clinical trials are crucial to understanding how drugs and therapies work, how safe they are in humans, and how effective they are in treating cancer. They are vital for making...

Vienna, Austria, 14 December 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter Llewellyn-Davies will present a corporate update during...

1. What are the current main characteristics of clinical trials for cancer treatments? Sarah Bischof: Oncology is a leading area for innovative R&D on many metrics – whether number of...

Poster presentation shows treatment with APN401, an autologous cell therapy product targeting the master immune checkpoint Cbl-b, resulted in stabilization of disease for more than six months in a heavily...

Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2 Investigators recommend further development of inhaled APN01, which…